CMS enforces requirement for State Medicaid programs to provide Medication-Assisted Treatment

Image of GettyImages-1174322066.jpg

Key Takeaways

On October 1, the Center for Medicaid and Medicare Services (CMS) issued a reminder notice to state Medicaid programs that they must now cover all forms of drugs and biologicals approved or licensed by the U.S. Food and Drug Administration (FDA) for Medication Assisted Treatment (MAT) as mandatory benefit to be used for the treatment of Opioid Use Disorder (OUD).

The requirement was first set in statute by the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities (SUPPORT) Act of 2018 (P.L. 115-271), a broad bipartisan legislation enacted to help combat the opioid epidemic. The mandate was established under section 1905(a)(29) of the SUPPORT Act, which amended the Social Security Act by adding MAT as a Medicaid covered service.

Medication Assisted Treatment (MAT) involves the use of medication along with counseling and other behavioral health therapies to treat substance use disorders — primarily opioid use disorder — and prevent overdose. The choice and dosage of medication is tailored to each patient, following a thorough assessment by a licensed physician that accounts for a patient’s different situations such as pregnancy, mental illness or incarceration.

While the intended goal of this mandate was to increase access to evidence-based treatment for opioid use disorder, there has been concern by some lawmakers that the requirement would increase state coverage obligations without the financial support of Medicaid rebates, which help offset the cost of prescription drugs covered under the program. The notice addresses these concerns by ensuring the state’s ability to seek additional Medicaid revenue through drug rebates and clarifying that drug manufacturers will be required to pay the appropriate rebates and must comply with applicable pricing and reporting requirements.

As an integral part of the federal-state-local partnership in the Medicaid program, counties are invested in changes to the program that impact the services and revenue sources. NACo supports the use of MAT for the treatment of opioid use disorder and other addictions, while also advocating for increased funding flexibility that does not shift cost burdens to local government. NACo will continue to monitor the impact of this mandate on both the accessibility of treatment and any potential fiscal impacts on counties.

Additional Resources:

Image of GettyImages-1174322066.jpg

Tagged In:

Attachments

Related News

Man at call center
Advocacy

FCC takes critical steps to improve the 988 National Suicide Lifeline

On March 21, bipartisan congressional leaders and FCC Chairwoman Jessica Rosenworcel announced steps to improve the 988 National Suicide Lifeline. This announcement marks major progress on the nation’s crisis response, a priority for counties and a key policy pillar of the NACo Commission on Mental Health and Wellbeing.

Nurse and older man
Advocacy

House Ways and Means Committee passes bill blocking proposed CMS nursing home minimal staffing rule

On March 5, the U.S. House of Representatives Committee on Ways and Means marked up and reported out of committee the Protect America’s Senior’s Access to Care Act (H.R. 7513). 

Nurse and doctor
Advocacy

HHS releases final rule on substance use confidentiality

In February, the U.S. Department of Health & Human Services (HHS) introduced a Final Rule amending the regulations governing the Confidentiality of Substance Use Disorder Patient Records at 42 CFR part 2.